摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-(4-Benzyloxy-benzyl)-4-(5-furan-2-yl-2H-[1,2,4]triazol-3-yl)-2H-pyrazol-3-ylamine | 207233-81-6

中文名称
——
中文别名
——
英文名称
2-(4-Benzyloxy-benzyl)-4-(5-furan-2-yl-2H-[1,2,4]triazol-3-yl)-2H-pyrazol-3-ylamine
英文别名
4-[5-(furan-2-yl)-1H-1,2,4-triazol-3-yl]-2-[(4-phenylmethoxyphenyl)methyl]pyrazol-3-amine
2-(4-Benzyloxy-benzyl)-4-(5-furan-2-yl-2H-[1,2,4]triazol-3-yl)-2H-pyrazol-3-ylamine化学式
CAS
207233-81-6
化学式
C23H20N6O2
mdl
——
分子量
412.451
InChiKey
HZVWRTMZLMZWFA-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.4
  • 重原子数:
    31
  • 可旋转键数:
    7
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.09
  • 拓扑面积:
    108
  • 氢给体数:
    2
  • 氢受体数:
    6

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    2-(4-Benzyloxy-benzyl)-4-(5-furan-2-yl-2H-[1,2,4]triazol-3-yl)-2H-pyrazol-3-ylamine 在 palladium on activated charcoal N-甲基吡咯烷酮氢气对甲苯磺酸 作用下, 以 1,4-二氧六环甲醇 为溶剂, 25.0~160.0 ℃ 、344.73 kPa 条件下, 反应 4.0h, 生成 5-amino-7-[4-hydroxybenzyl]-2-(furan-2-yl)-pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine
    参考文献:
    名称:
    Design, Synthesis, and Biological Evaluation of a Second Generation of Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as Potent and Selective A2A Adenosine Receptor Antagonists
    摘要:
    New A(2A) adenosine receptor antagonists in the series of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]-pyrimidines, bearing oxygenated substituents on the phenylalkyl chains on the 7-position, have been synthesized. The compounds were tested in binding and functional assays to evaluate affinity, potency, and selectivity for rat A(2A) compared to rat A(1) and human A(3) receptor subtypes. The most interesting compounds (5d,e,h) were tested also in binding to human A(1) and A(2A) adenosine receptors. They showed very good affinity (K-i = 0.94 nM for compound 5h) and interesting selectivity with respect to both rA(1) and hA(3) (compound 5h: rA(1)/rA(2A) = 787, hA(3)/rA(2A) > 10000) These important findings make this new series of compounds the first really selective for A(2A) adenosine receptors. Thermodynamic parameters were evaluated; all the tested compounds displayed an enthalpy-driven binding as expected for antagonists. Moreover, compound 5h showed a negative entropy value. The highly negative enthalpic and entropic contributions could mean that 5h fits very well in the binding site where, probably, an electrostatic interaction is present associated to a scarce solvent reorganization around the receptor binding site. These compounds deserve to be further developed to assess their potential for treatment of neurodegenerative disorders such as Parkinson's disease.
    DOI:
    10.1021/jm9708689
  • 作为产物:
    参考文献:
    名称:
    Design, Synthesis, and Biological Evaluation of a Second Generation of Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as Potent and Selective A2A Adenosine Receptor Antagonists
    摘要:
    New A(2A) adenosine receptor antagonists in the series of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]-pyrimidines, bearing oxygenated substituents on the phenylalkyl chains on the 7-position, have been synthesized. The compounds were tested in binding and functional assays to evaluate affinity, potency, and selectivity for rat A(2A) compared to rat A(1) and human A(3) receptor subtypes. The most interesting compounds (5d,e,h) were tested also in binding to human A(1) and A(2A) adenosine receptors. They showed very good affinity (K-i = 0.94 nM for compound 5h) and interesting selectivity with respect to both rA(1) and hA(3) (compound 5h: rA(1)/rA(2A) = 787, hA(3)/rA(2A) > 10000) These important findings make this new series of compounds the first really selective for A(2A) adenosine receptors. Thermodynamic parameters were evaluated; all the tested compounds displayed an enthalpy-driven binding as expected for antagonists. Moreover, compound 5h showed a negative entropy value. The highly negative enthalpic and entropic contributions could mean that 5h fits very well in the binding site where, probably, an electrostatic interaction is present associated to a scarce solvent reorganization around the receptor binding site. These compounds deserve to be further developed to assess their potential for treatment of neurodegenerative disorders such as Parkinson's disease.
    DOI:
    10.1021/jm9708689
点击查看最新优质反应信息

文献信息

  • Design, Synthesis, and Biological Evaluation of a Second Generation of Pyrazolo[4,3-<i>e</i>]-1,2,4-triazolo[1,5-<i>c</i>]pyrimidines as Potent and Selective A<sub>2A</sub> Adenosine Receptor Antagonists
    作者:Pier Giovanni Baraldi、Barbara Cacciari、Giampiero Spalluto、Manuela Bergonzoni、Silvio Dionisotti、Ennio Ongini、Katia Varani、P. A. Borea
    DOI:10.1021/jm9708689
    日期:1998.6.1
    New A(2A) adenosine receptor antagonists in the series of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]-pyrimidines, bearing oxygenated substituents on the phenylalkyl chains on the 7-position, have been synthesized. The compounds were tested in binding and functional assays to evaluate affinity, potency, and selectivity for rat A(2A) compared to rat A(1) and human A(3) receptor subtypes. The most interesting compounds (5d,e,h) were tested also in binding to human A(1) and A(2A) adenosine receptors. They showed very good affinity (K-i = 0.94 nM for compound 5h) and interesting selectivity with respect to both rA(1) and hA(3) (compound 5h: rA(1)/rA(2A) = 787, hA(3)/rA(2A) > 10000) These important findings make this new series of compounds the first really selective for A(2A) adenosine receptors. Thermodynamic parameters were evaluated; all the tested compounds displayed an enthalpy-driven binding as expected for antagonists. Moreover, compound 5h showed a negative entropy value. The highly negative enthalpic and entropic contributions could mean that 5h fits very well in the binding site where, probably, an electrostatic interaction is present associated to a scarce solvent reorganization around the receptor binding site. These compounds deserve to be further developed to assess their potential for treatment of neurodegenerative disorders such as Parkinson's disease.
查看更多